MA42440A - Anticorps qui se lient à la sortiline et inhibent la liaison de la progranuline - Google Patents

Anticorps qui se lient à la sortiline et inhibent la liaison de la progranuline

Info

Publication number
MA42440A
MA42440A MA042440A MA42440A MA42440A MA 42440 A MA42440 A MA 42440A MA 042440 A MA042440 A MA 042440A MA 42440 A MA42440 A MA 42440A MA 42440 A MA42440 A MA 42440A
Authority
MA
Morocco
Prior art keywords
sortiline
antibodies
bind
inhibit
progranulin binding
Prior art date
Application number
MA042440A
Other languages
English (en)
Other versions
MA42440B1 (fr
Inventor
Rønn Lars Christian Biilmann
Søren Christensen
Jong Rob De
Jan Egebjerg
Arnout Gerritsen
Ibrahim John Malik
Paul Parren
Jeffrey B Stavenhagen
Den Brink Edward Van
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA42440A publication Critical patent/MA42440A/fr
Publication of MA42440B1 publication Critical patent/MA42440B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA42440A 2015-07-13 2016-07-12 Anticorps contre la sortilin qui inhibent la liason à la progranulin MA42440B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1512215.3A GB201512215D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods
EP16739087.1A EP3322726B1 (fr) 2015-07-13 2016-07-12 Anticorps contre la sortilin qui inhibent la liason à la progranulin
PCT/EP2016/066516 WO2017009327A1 (fr) 2015-07-13 2016-07-12 Anticorps qui se lient à la sortiline et inhibent la liaison de la progranuline

Publications (2)

Publication Number Publication Date
MA42440A true MA42440A (fr) 2018-05-23
MA42440B1 MA42440B1 (fr) 2025-05-30

Family

ID=54013862

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42440A MA42440B1 (fr) 2015-07-13 2016-07-12 Anticorps contre la sortilin qui inhibent la liason à la progranulin

Country Status (35)

Country Link
US (6) US10479835B2 (fr)
EP (1) EP3322726B1 (fr)
JP (2) JP6979397B2 (fr)
KR (1) KR102778576B1 (fr)
CN (3) CN107849135A (fr)
AR (1) AR105335A1 (fr)
AU (1) AU2016292980B2 (fr)
BR (1) BR112018000771A2 (fr)
CA (1) CA2989739A1 (fr)
CL (2) CL2018000092A1 (fr)
CO (1) CO2017012988A2 (fr)
CR (1) CR20180002A (fr)
DO (1) DOP2018000014A (fr)
EA (1) EA201890038A1 (fr)
EC (1) ECSP18002725A (fr)
ES (1) ES3024469T3 (fr)
GB (1) GB201512215D0 (fr)
HR (1) HRP20250602T1 (fr)
HU (1) HUE071424T2 (fr)
IL (1) IL256503B (fr)
JO (1) JO3710B1 (fr)
MA (1) MA42440B1 (fr)
MX (1) MX2018000506A (fr)
NI (1) NI201800007A (fr)
PE (1) PE20181014A1 (fr)
PH (1) PH12018500100A1 (fr)
PL (1) PL3322726T3 (fr)
RS (1) RS66856B1 (fr)
RU (1) RU2735639C2 (fr)
SV (1) SV2018005613A (fr)
TN (1) TN2017000534A1 (fr)
TW (1) TWI760305B (fr)
UA (1) UA125136C2 (fr)
WO (1) WO2017009327A1 (fr)
ZA (1) ZA201708613B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164608A1 (fr) 2015-04-07 2016-10-13 Alector Llc Procédés de recherche par criblage d'antagonistes de liaison à la sortiline
EP3991748A3 (fr) 2015-04-07 2022-08-24 Alector LLC Anticorps anti-sortiline et leurs procédés d'utilisation
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
SMT202300110T1 (it) * 2018-07-13 2023-05-12 Alector Llc Anticorpi anti-sortilina e relativi metodi di uso
EP3666281A1 (fr) * 2018-12-14 2020-06-17 Insusense ApS Compositions comprenant sortilin-1
MX2021012335A (es) * 2019-04-10 2021-11-12 Regeneron Pharma Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.
BR112022012230A2 (pt) * 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
AU2021297540A1 (en) * 2020-06-24 2023-02-02 Prothena Biosciences Limited Antibodies recognizing sortilin
US20250345446A1 (en) 2022-06-23 2025-11-13 Draupnir Bio Aps Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes
CN118496354A (zh) * 2023-02-15 2024-08-16 三优生物医药(上海)有限公司 包含共同轻链的抗体库、其制备方法及其用途
WO2025031098A1 (fr) * 2023-08-09 2025-02-13 瑞诺元(苏州)生物科技有限公司 Nanoanticorps spécifique de la sortiline 1, vaa recombinant le contenant et utilisation
WO2025132764A1 (fr) * 2023-12-21 2025-06-26 Amylonix Ab Polypeptide de liaison à la sortiline

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2065299C (fr) 1989-08-09 2001-07-24 Buck A. Rhodes Radio-etiquetage direct des anticorps et d'autres proteines a l'aide de technetium ou de rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5101990A (en) 1990-03-23 1992-04-07 Continental Pet Technologies, Inc. Stretch blow molded oblong or oval container
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
EP0593592B1 (fr) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Copolymere en masse segmentee a cristaux liquides thermotropiques
AU693436B2 (en) 1993-03-09 1998-07-02 Genzyme Corporation Isolation of components of interest from milk
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
CN1399645A (zh) 1999-07-29 2003-02-26 米德列斯公司 Her2/neu的人单克隆抗体
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
DK1891966T3 (da) 2002-12-20 2012-04-02 Lundbeck & Co As H Modulation af neurotrophinaktivitet; fremgangsmåde til screening
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
PL3225251T3 (pl) 2006-12-21 2020-06-29 H. Lundbeck A/S Modulacja aktywności proneurotrofin
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
WO2009132656A2 (fr) 2008-04-27 2009-11-05 H. Lundbeck A/S Mise au point de ligands spécifiques de la sortiline
JP2011524741A (ja) 2008-05-27 2011-09-08 協和発酵キリン株式会社 インターロイキン１０受容体（ｉｌ−１０ｒ）抗体及び使用方法
WO2010022175A1 (fr) * 2008-08-19 2010-02-25 Yale University Identification de la sortiline en tant que récepteur neuronal pour la protéine de la démence frontotemporale, la progranuline
EP3165537A1 (fr) 2008-12-19 2017-05-10 H. Lundbeck A/S Modulation de la famille de récepteurs à domaine vps10 pour le traitement de troubles mentaux et du comportement
RU2536232C2 (ru) * 2011-07-01 2014-12-20 Олег Ильич Эпштейн Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
JP6239635B2 (ja) 2012-11-02 2017-11-29 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 血管石灰化の誘導因子であるソルチリン１
EP3991748A3 (fr) * 2015-04-07 2022-08-24 Alector LLC Anticorps anti-sortiline et leurs procédés d'utilisation
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
SMT202300110T1 (it) 2018-07-13 2023-05-12 Alector Llc Anticorpi anti-sortilina e relativi metodi di uso

Also Published As

Publication number Publication date
US11548950B2 (en) 2023-01-10
AU2016292980B2 (en) 2022-10-06
ZA201708613B (en) 2021-03-31
MA42440B1 (fr) 2025-05-30
RU2735639C2 (ru) 2020-11-05
CL2018000092A1 (es) 2018-07-06
EA201890038A1 (ru) 2018-06-29
IL256503B (en) 2022-02-01
TWI760305B (zh) 2022-04-11
MX2018000506A (es) 2018-05-11
JO3710B1 (ar) 2021-01-31
RS66856B1 (sr) 2025-06-30
KR20180030045A (ko) 2018-03-21
JP2018529635A (ja) 2018-10-11
RU2018100824A3 (fr) 2020-01-17
US10428147B2 (en) 2019-10-01
DOP2018000014A (es) 2018-04-15
EP3322726C0 (fr) 2025-03-12
SV2018005613A (es) 2018-02-23
CO2017012988A2 (es) 2018-05-21
US20200190188A1 (en) 2020-06-18
US20210269524A1 (en) 2021-09-02
GB201512215D0 (en) 2015-08-19
HRP20250602T1 (hr) 2025-07-18
KR102778576B1 (ko) 2025-03-07
UA125136C2 (uk) 2022-01-19
US20250277040A1 (en) 2025-09-04
AU2016292980A1 (en) 2018-01-18
CN114478774A (zh) 2022-05-13
US20230159643A1 (en) 2023-05-25
IL256503A (en) 2018-02-28
TW201702273A (zh) 2017-01-16
PH12018500100A1 (en) 2018-07-30
US10889650B2 (en) 2021-01-12
PL3322726T3 (pl) 2025-06-23
HUE071424T2 (hu) 2025-08-28
CN114478775A (zh) 2022-05-13
EP3322726B1 (fr) 2025-03-12
WO2017009327A1 (fr) 2017-01-19
RU2018100824A (ru) 2019-08-13
ES3024469T3 (en) 2025-06-04
US20180305455A1 (en) 2018-10-25
US10479835B2 (en) 2019-11-19
CL2020002468A1 (es) 2021-01-29
JP6979397B2 (ja) 2021-12-15
CR20180002A (es) 2018-04-09
AR105335A1 (es) 2017-09-27
JP2022003058A (ja) 2022-01-11
US12331123B2 (en) 2025-06-17
HK1254356A1 (en) 2019-07-19
BR112018000771A2 (pt) 2018-09-25
US20170267761A1 (en) 2017-09-21
PE20181014A1 (es) 2018-06-26
EP3322726A1 (fr) 2018-05-23
TN2017000534A1 (en) 2019-04-12
CN107849135A (zh) 2018-03-27
ECSP18002725A (es) 2018-03-31
CA2989739A1 (fr) 2017-01-19
NI201800007A (es) 2018-10-18

Similar Documents

Publication Publication Date Title
FR23C1036I2 (fr) Anticorps qui se lient à il-23
IL285375A (en) Il-8-binding antibodies and uses thereof
MA49565A (fr) Anticorps agonistes qui lient cd137 humain et leurs utilisations
EP3370769A4 (fr) Anticorps se liant spécifiquement à tim-3 et leurs utilisations
HRP20181802T1 (hr) Protutijela koja vežu humani cd3
MA49846A (fr) Anticorps qui se lient à l'egfr et à cmet
EP3529279A4 (fr) Agents de liaison à cd133 et leurs utilisations
EP3708589A4 (fr) ANTICORPS BISPÉCIFIQUE QUI SE LIE À CD40 ET À EpCAM
IL259834A (en) Heterodimeric antibodies that bind cd3 and psma
LT3328889T (lt) Bispecifinio antikūno konstruktai, prisirišantys prie dll3 ir cd3
MA41313A (fr) Anticorps de liaison de la protéine april modifiés
EP3303379A4 (fr) Agents de liaison à tigit et leurs utilisations
EP3452089A4 (fr) Protéines de liaison bispécifiques et leurs utilisations
PT3592384T (pt) Anticorpos que se ligam especificamente ao il-1r7 humano
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
MA44072A (fr) Anticorps se liant spécifiquement à hla-dr et leurs utilisations
EP2953971A4 (fr) Protéines de liaison à il-11r et leurs utilisations
EP2864358A4 (fr) Protéines de liaison à un antigène qui se lient à ccr2
EP3328994A4 (fr) Protéines de liaison d'antigène ciblant cd56 et leurs utilisations
LT3558369T (lt) Antikūnai, kurie specifiškai rišasi prie žmogaus il-15, ir jų panaudojimo būdai
PT3274370T (pt) Anticorpos anti-ceacam6 e utilizações dos mesmos
IL256503B (en) Antibodies that bind sortilin and inhibit binding to progranulin
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
MA39708A (fr) Anticorps qui se lient au récepteur cannabinoïde 1 (cb1) humain
MA41480A (fr) Anticorps qui se lient au ccr6 et leurs utilisations